非抗凝策略旨在预防新生心房动的初级中风
Luca Sgarra1, Vanessa Desantis2, Andrea Matteucci3,4
1Cardiology Unit, Medicine Department, General Hospital "F. Miulli" Acquaviva delle Fonti, 70021 Bari, Italy.
Biomedicines
|March 28, 2025
概括
由于监测技术,新生的心房 (nAF) 检测率正在上升. 本综述探讨了在抗凝血不适时管理nAF的抗抽血药物策略.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 药理学 药理学 是一个学科.
背景情况:
- 新生的心房动 (nAF) 越来越多地通过广泛的心率监测技术来检测.
- 由于CHA2DS2-VA得分较低,风险/益处比较不确定,临床医生在没有明确的抗凝药指示的情况下,面临着管理新发性AF的挑战.
- 传统的治疗范式可能会忽视对nAF管理具有抗发作潜力的药理选择.
研究的目的:
- 审查和阐明新生的心房动 (nAF) 的治疗策略.
- 探索药物具有抗发作潜力的药物在管理nAF.在管理中的作用.
- 总结nAF的预防机制和治疗方法.
主要方法:
- 关于新生的心房动 (nAF) 管理研究的文献综述.
- 分析具有抗中风性质的药理选择.
- 对nAF的桥梁和整合策略的证据综合.
主要成果:
- 新生的心房动 (nAF) 提出了独特的管理挑战.
- 具有抗震动潜力的药物为nAF提供了治疗途径.
- 这些策略可以作为抗凝血的桥梁或补充.
结论:
- 新生的心房 (nAF) 的有效管理需要探索替代药理策略.
- 抗抽血药物在管理nAF方面表现有前途,为抗凝药提供桥梁或并行疗法.
- 对这些策略的进一步研究对于优化nAF患者护理至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
532
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
532
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
986
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
986
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388
Clot Retraction and Fibrinolysis
2.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.4K


